The DOI matches its Crossref record.
Hormonal regulation of prostate‐specific antigen (PSA) glycoprotein in the human prostatic adenocarcinoma cell line, LNCaP
Abstract
Prostate‐specific antigen (PSA) has emerged as the most useful marker for management of patients with prostate cancer. The regulation of this glycoprotein in vivo has important clinical implications. Indirect evidence indicates that the PSA glycoprotein might be regulated by androgens, and previous studies in this laboratory have demonstrated that PSA mRNA is upregulated by androgens. The current work reports a detailed study of PSA glycoprotein expression as influenced by steroid hormones in a human prostatic adenocarcinoma cell line, LNCaP. First, we have examined the steroid binding specificity of the androgen receptor in this cell line. In comparison with wild‐type rat androgen receptor in prostate, the receptor in LNCaP cells has altered affinity for a number of steroids or analogs such as progesterone (R5020), antiprogesterone (RU486), two antiandrogens (cyperoterone acetate and hydroxyflutamide), and an androgen metabolite (epitestosterone). However, its affinity for androgens (mibolerone, dihydrotestosterone, and testosterone) is not changed. The receptor does not bind to the synthetic glucocorticoids (triaminolone acetonide and dexamethasone) nor to a synthetic estrogen DES (diethylstilbestrol). The change of the steroid binding specificity of the receptor is correlated with a single mutation (A → G at nucleotide #876 relative to the initiation codon) of the steroid binding domain of the receptor. The mutation and alteration of steroid‐binding specificity of the androgen receptor is also correlated with PSA glycoprotein expression affected by different ligands tested. We have demonstrated that the PSA glycoprotein is upregulated by androgens and is affected by neither epidermal growth factor nor basic fibroblast growth factor. Moreover, PSA glycoprotein could be induced by R5020, estradiol, and epitestosterone; but neither glucocorticoids nor DES had any effect on PSA induction. Interestingly, although the antiandrogen, cyperotone acetate, had the ability to induce PSA, both RU486 and hydroxyflutamide could block androgen and progesterone induction of PSA glycoprotein. Therefore, we conclude that the PSA glycoprotein expression is influenced predominantly by androgens via its receptor, and the mutation of the receptor can affect the expression of this cellular gene by the steroids other than androgens.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Dietary flavonoids: Effects on xenobiotic and carcinogen metabolism
Moon, Y. J., Wang, X., & Morris, M. E. (2006) · Toxicology in Vitro · doi:10.1016/j.tiv.2005.06.048 · Cited by 869
Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy
Wright, G. L., Mayer Grob, B., Haley, C., Grossman, K., Newhall, K., Petrylak, D., Troyer, J., Konchuba, A., Schellhammer, P. F., & Moriarty, R. (1996) · Urology · doi:10.1016/s0090-4295(96)00184-7 · Cited by 635
Xing, N. (2001) · Carcinogenesis · doi:10.1093/carcin/22.3.409 · Cited by 416
Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer.
Scher, H. I., & Kelly, W. K. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.8.1566 · Cited by 405
Hsieh, T.-C., & Wu, J. M. (1999) · Experimental Cell Research · doi:10.1006/excr.1999.4471 · Cited by 361
Induction of apoptosis in breast cancer cells MDA-MB-231 by genistein
Li, Y., Upadhyay, S., Bhuiyan, M., & Sarkar, F. H. (1999) · Oncogene · doi:10.1038/sj.onc.1202650 · Cited by 319
Prostate-specific Antigen Expression Is Regulated by an Upstream Enhancer
Schuur, E. R., Henderson, G. A., Kmetec, L. A., Miller, J. D., Lamparski, H. G., & Henderson, D. R. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.12.7043 · Cited by 305
Lawrence, M. G., Lai, J., & Clements, J. A. (2010) · Endocrine Reviews · doi:10.1210/er.2009-0034 · Cited by 265
Murillo, H. (2001) · Endocrinology · doi:10.1210/en.142.11.4795 · Cited by 263
Periyasamy, S., Warrier, M., Tillekeratne, M. P. M., Shou, W., & Sanchez, E. R. (2007) · Endocrinology · doi:10.1210/en.2007-0145 · Cited by 78
Saporita, A. J., Ai, J., & Wang, Z. (2007) · The Prostate · doi:10.1002/pros.20541 · Cited by 77
Evidence of androgen action in endometrial and ovarian cancers
Gibson, D. A., Simitsidellis, I., Collins, F., & Saunders, P. T. K. (2014) · Endocrine-Related Cancer · doi:10.1530/erc-13-0551 · Cited by 73
“Prostate-specific antigen (PSA/KLK3) is an androgenregulated gene that has been extensively investigated in the context of prostate cancer (Montgomery et al. 1992).”
BackgroundAndrogen Receptor Mutations in Carcinoma of the Prostate: Significance for Endocrine Therapy
Culig, Z., Klocker, H., Bartsch, G., & Hobisch, A. (2001) · American Journal of PharmacoGenomics · doi:10.2165/00129785-200101040-00001 · Cited by 50
Metadata
- Authors
- Montgomery, B. T., Young, C. Y. ‐., Bilhartz, D. L., Andrews, P. E., Thompson, N. F., Tindall, D. J., & Prescott, J. L.
- Venue
- The Prostate
- Publisher
- Wiley
- Published
- 1992-01
- Volume
- 21
- Issue
- 1
- Pages
- 63-73
- ISSN
- 0270-4137 (ISSN-L)
- 1097-0045
- OpenAlex
- W2151275516
- Cited by
- 178
- References
- 0
- FWCI
- 10.42
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.